QUEBEC CITY, Sept. 7, 2016 /CNW Telbec/ - Opsens Inc.
("Opsens") (TSXV: OPS) (OTCQX: OPSSF) is pleased to announce
the appointment of Mr Pat Mackin as
a Director of the Company.
"We are delighted to see Pat, a renowned leader in the medical
device industry, join us. His expertise as head of leading
companies in the cardiovascular space will be valuable as we step
up from limited market release to a wider one," said Louis Laflamme, President and CEO of Opsens.
Pat Mackin brings over 25 years
of experience in the medical device industry. Since September 2014, Mr Mackin has been President
and Chief Executive Officer of CryoLife, Inc. (NYSE:CRY)
("CryoLife"), a leader in the manufacturing, processing, and
distribution of implantable living tissues and medical devices used
in cardiac surgical procedures. CryoLife markets and
sells products in more than 80 countries worldwide.
Before joining CryoLife, he was President of the Cardiac Rhythm
Disease Management Division at Medtronic, Inc. (NYSE:MDT)
("Medtronic"). Previously, also at Medtronic, he held the positions
of Vice President, Vascular, Western
Europe where he launched the Company's first drug-eluding
stent called "Endeavour" and Vice President and General Manager,
Endovascular Business Unit. Prior to joining Medtronic, Mr Mackin
worked for six years at Genzyme, Inc. serving as Senior Vice
President and General Manager for the Cardiovascular Surgery
Business Unit and as Director of Sales, Surgical Products division.
Before joining Genzyme, Mr Mackin spent five years at
Deknatel/Snowden-Pencer, Inc. in various sales and marketing roles
and three years as an Officer in the U.S. Army. Mr Mackin received
an MBA from the Kellogg Graduate School of Management at
Northwestern University and is a
graduate of the U.S. Military Academy at West
Point.
GRANT OF STOCK OPTIONS
On September 7, 2016, Opsens'
Board of Directors approved the grant of 100,000 stock options to
Pat Mackin, pursuant to Opsens'
Stock Option Plan adopted by shareholders on January 18, 2016.
Under the provisions of Opsens' stock option plan, each stock
option granted entitles the holder to subscribe to one Opsens'
common share at the latest on September 6,
2021 at a price of $1.50 per
share. The stock options granted allow the holder to subscribe
immediately for common stock of Opsens.
About Opsens Inc. (www.opsens.com or
www.opsensmedical.com)
Opsens focuses mainly on the measure of FFR in interventional
cardiology. Opsens offers an advanced optical-based pressure
guidewire (OptoWire) that aims at improving the clinical outcome of
patients with coronary artery disease. Opsens is also involved in
industrial activities. The Company develops, manufactures and
installs innovative fibre optic sensing solutions for critical
applications, such as the monitoring of oil wells and other
demanding industrial applications.
Forward-looking statements contained in this press release
involve known and unknown risks, uncertainties and other factors
that may cause actual results, performance and achievements of
Opsens to be materially different from any future results,
performance or achievements expressed or implied by the said
forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE OPSENS INC.